Epinephrine pre-filled syringe - Adamis Pharmaceuticals Corporation

Drug Profile

Epinephrine pre-filled syringe - Adamis Pharmaceuticals Corporation

Alternative Names: Epinephrine injection PFS - Adamis Pharmaceuticals; Epinephrine PFS - Adamis Pharmaceuticals; Symjepi

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adamis Pharmaceuticals Corporation
  • Class Antiarrhythmics; Antihaemorrhagics; Antihypotensives; Bronchodilators; Catecholamines; Ethanolamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Anaphylaxis

Most Recent Events

  • 02 Jul 2018 Sandoz (division of the Novartis group) in-licenses sales and marketing rights for Symjepi™ from Adamis Pharmaceutical Corporation in the US
  • 15 Mar 2018 Adamis Pharmaceuticals Corporation expects FDA approval for epinephrine pre-filled syringe (0.15mg) in the second half of 2018
  • 12 Feb 2018 The US FDA is targeting 03/09/2018 to communicate proposed labelling and, if required, any postmarketing requirement/commitment requests for epinephrine pre-filled syringe's (0.15mg) sNDA for Anaphylaxis (In adolescents, In children [weighing 33 - 65 pounds])
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top